 IRVINE, Calif., Sept. 09, 2021 GLOBE NEWSWIRE -- Reneo Pharmaceuticals, Inc. NASDAQ: RPHM, a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that management will be participating in five investor conferences during the month of September. 